After Merck’s success with a P2X3 inhibitor hopes were high for Bellus’s similar compound. They are now dashed.
Approval decisions are due for Jazz, Gilead and Galapagos in July, while Glaxo is preparing for a panel.
Good news for patients whose cough is not caused by Covid-19: Merck’s chronic cough pill is a step closer to market. But tolerability questions remain.
Amarin’s Vascepa and Allergan’s migraine project ubrogepant are the high-profile pending FDA approval decisions as the sector heads into the last month of the year.
Smaller projects dominate the list, but this doesn’t make them any less important for November’s hopefuls.
A new influenza antiviral from Roche and Shionogi could become an important new medicine for both groups, if payers can be convinced.